Asymptomatic varicose veins of lower extremities
Conditions
Interventions
This is a two-arm, non-blind, randomized controlled clinical study by sortition. Experimental group: 30 patients with varicose veins of the lower limbs without disease in the saphenous veins (magna an
Sponsors
MEDCOG Treinamentos, Locações e Organizações de Eventos em Angiologia e Cirurgia Vascular Ltda
MEDCOG Treinamentos, Locações e Organizações de Eventos em Angiologia e Cirurgia Vascular Ltda
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Pacients aged between 18 and 60 years; of both genders; with Chronic Venous Disease – CVD; able to understand and sign (or their representative) the Informed Consent Form ICF
Exclusion criteria
Exclusion criteria: Patients with insufficient perforating veins or saphenous veins (magna and/or parva) detected on ultrasound examination; pregnancy; puerperium; peripheral arterial disease; known thrombophilia; previous history of thrombosis; use of anticoagulants; allergy to polidocanol; active infectio; history of asthma and migraine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to evaluate whether there was a reduction in symptoms and an improvement in quality of life with the association of MPFF 1000mg/day with foam sclerotherapy treatment in relation to foam sclerotherapy treatment alone. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to evaluate whether there was a reduction in complications (hyperpigmentation and “matting”) and an improvement in general patient satisfaction with the association of MPFF 1000mg/day with foam sclerotherapy treatment in relation to foam sclerotherapy treatment alone. | — |
Countries
Brazil
Contacts
Public ContactRodrigo Kikuchi
MEDCOG Treinamentos, Locações e Organizações de Eventos em Angiologia e Cirurgia Vascular Ltda
Outcome results
None listed